<DOC>
	<DOCNO>NCT02322450</DOCNO>
	<brief_summary>2QG1 Phase IIa study aim assess blood pressure lower effect 4-week administration QGC001 oral dos patient grade I II essential hypertension compare placebo , assess safety tolerability , obtain preliminary PK information QGC001 give multiple oral dos determine preliminary PD profile QGC001 multiple oral dos plasma urine hormone , compare placebo .</brief_summary>
	<brief_title>Phase IIa Study Product QGC001 Compared With Placebo Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Male female nonchildbearing potential patient ( postmenopausal since least 12 month surgically sterilize ) age 18 75 year ; Body weight ≥50 kg body mass index ( BMI ) calculate weight kg/ ( height m2 ) 18 40 kg/m2 screening ; A sign date informed consent form studyspecific screen procedure perform ; With diagnosis essential grade I II hypertension define : supine office systolic BP ( SBP ) 140159 mmHg diastolic BP ( DBP ) 9099 mmHg additional clinical indication accord ESH guideline antihypertensive treatment 2week placebo runin period , supine office SBP 160179 mmHg DBP 100109 mmHg 2week placebo runin period diagnosis essential grade II hypertension ; Diagnosis permanent hypertension confirm mean SBP DBP high than135 85 mmHg daytime ambulatory blood pressure monitoring ( ABPM ) 2week placebo runin period ; Estimated glomerular filtration rate ( Modification Diet Renal Disease ( MDRD ) formula ) ≥ 60 ml/min/1.73 m2 . Any significant hepatic , renal , respiratory ( e.g. , asthma ) , gastrointestinal , endocrine ( e.g. , diabetes , dyslipidemia necessitate drug therapy ) , immunologic , dermatological , hematological , neurologic , psychiatric disease history clinically important drug allergy ; Acute disease state ( e.g. , vomit , fever , diarrhea ) within 7 day study day 1 ; Any history transient ischemic accident ( TIA ) cerebrovascular accident ( CVA ) ; Any history acute heart failure heart failure ; Any history myocardial infarction , unstable angina , coronary bypass percutaneous coronary angioplasty ; History malignant tumor past 5 year ; Any medical surgical disorder consider investigator increase risk participation study , liable prevent patient comply requirement study continue study completion ; Any situation , investigator 's opinion , might compromise assessment efficacy safety ; History nonadherence treatment ; History drug abuse within 1 year study day 1 ; History alcoholism within 1 year day 1 ; Positive serologic finding human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , and/or hepatitis C virus ( HCV ) antibody ; Use investigational drug within 30 day IMP administration ; Donation blood ( i.e. , 500 ml ) within 90 day study day 1 ; Known secondary hypertension ; Grade III hypertension ; Estimated glomerular filtration rate ( MDRD formula ) 60 ml/min/1.73 m2 ; Type I diabetes mellitus uncontrolled type II diabetes mellitus ( HbA1C ≥ 8 % ) ; Severe obesity ( BMI ≥ 40 kg/m2 ) ; Arm circumference ≥ 42 cm ; Atrial fibrillation ; Known hypersensitivity drug ; History spontaneous drug induce angioneurotic edema ; Use follow medication within four ( 4 ) week prior dose : Thyroid medication , statin therapy , oral antidiabetic drug , estrogen replacement therapy and/or chronic low dose aspirin ( 75 mg/day ) unless patient stable maintenance dose least 3 month prior screen . Anticoagulant treatment Cholestyramine resins . Treatment oral , topical , inhaled , eye drop corticosteroid Treatment class Ia , Ib Ic III antiarrhythmic CNS drug Pglycoprotein ( Pgp ) inhibitor ( e.g. , verapamil , quinidine , ritonavir ) , know cytochrome P450 inducer inhibitor ( eg , ketoconazole/CYP3A4 , quinidine/CYP2D6 , gemfibrozil/CYP2C8 ) Chronic use nonsteroidal antiinflammatory drug ( NSAIDS ) cyclooxygenase ( COX ) 2 inhibitor . Vasodilators vascular muscle relaxant prescribed condition Unlikely cooperate study and/or poor compliance anticipate investigator , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study ; Participation another interventional study time within 3 month prior begin present study ; Participant affiliate French social security ; No write informed consent ; A mark baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) ; A history additional risk factor Torsade de Pointes ( TdP ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) ; The use concomitant medication prolong QT/QTc interval .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>